Sildenafil topical - Dare Bioscience/Strategic Science and Technologies
Alternative Names: DARE to PLAY; Sildenafil citrate cream 5%; Sildenafil citrate topical cream (5%); Sildenafil cream (3.6%); Sildenafil cream 3.6%; SST-6007; Topical 5% sildenafil citrate creamLatest Information Update: 28 Aug 2026
At a glance
- Originator Strategic Science & Technologies
- Developer Dare Bioscience; Strategic Science & Technologies
- Class Antihypertensives; Erectile dysfunction therapies; Phenyl ethers; Piperazines; Purines; Pyrazoles; Pyrimidinones; Small molecules; Sulfonamides
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Female sexual dysfunction
Most Recent Events
- 26 Aug 2026 Pharmacokinetics and adverse events data from a phase I trial in Female sexual dysfunction released by Dare Bioscience
- 28 Jun 2026 No recent reports of development identified for phase-I development in Female-sexual-dysfunction(In volunteers) in Canada (Topical, Cream)
- 31 Mar 2025 Dare Bioscience plans to make Sildenafil topical cream available by prescription in December through a 503B compounding pathway